Worldwide Healthcare Trust PLC Edison issues review on Worldwide Healthcare Trust

TIDMWWH

Worldwide Healthcare Trust PLC

17 May 2016

London, UK, 17 May 2016

Edison issues research review on Worldwide Healthcare Trust

Worldwide Healthcare Trust (WWH) has a track record of more than 20 years investing in the healthcare sector. A change to its mandate six years ago has seen it expand its remit from pharmaceuticals and biotechnology to the whole healthcare sector. While the core of the portfolio is invested in US stocks, WWH is differentiated from the majority of peers by its c 15% weighting in emerging markets. The trust has substantially outperformed its benchmarks over three, five and 10 years and benefits from the stable management of manager Sam Isaly, a founding partner of specialist healthcare investment manager OrbiMed. The discount to NAV of c 7% is wider than long-term averages, suggesting potential to narrow from here.

At 16 May, WWH's shares were trading at a 7.3% discount to cum-income net asset value. This is a little wider than the target maximum discount of 6%, and also wider than the one-, three- and five-year averages (5.3%, 4.2% and 5.6% respectively). Given the historical support from share buybacks (c 457k shares bought back so far in 2016 at a cost of GBP7.9m), it is reasonable to expect the discount will narrow towards the long-term average, although in the run-up to the US presidential election, appetite for healthcare investments may remain subdued.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website: www.edisoninvestmentresearch.com

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

Contact details: Learn more at www.edisongroup.com and connect with Edison on:

 
 LinkedIn   www.linkedin.com/company/edison-investment-research 
---------  ---------------------------------------------------- 
 Twitter    www.twitter.com/Edison_Inv_Res 
---------  ---------------------------------------------------- 
 YouTube    www.youtube.com/edisonitv 
---------  ---------------------------------------------------- 
 Google+    https://plus.google.com/105425025202328783163/posts 
---------  ---------------------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRAARMATMBMBBLF

(END) Dow Jones Newswires

May 17, 2016 11:10 ET (15:10 GMT)